Inhibitor ribonukleotidne reduktaze

Iz Wikipedije, slobodne enciklopedije
Idi na navigaciju Idi na pretragu

Inhibitori ribonukleotidne reduktaze su familija antikancerni lekovi koji ometaju rast ćelija tumora blokiranjem formiranja dezoksiribonukleotida (gradivnih blokova DNK).

Primeri

Reference[uredi - уреди | uredi izvor]

  1. Zahedi Avval F, Berndt C, Pramanik A, Holmgren A (January 2009). "Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd)". Biochem. Biophys. Res. Commun. 379 (3): 775–9. PMID 19121624. doi:10.1016/j.bbrc.2008.12.128. 
  2. Mayhew CN, Phillips JD, Cibull ML, Elford HL, Gallicchio VS (September 2002). "Short-term treatment with novel ribonucleotide reductase inhibitors Trimidox and Didox reverses late-stage murine retrovirus-induced lymphoproliferative disease with less bone marrow toxicity than hydroxyurea". Antivir. Chem. Chemother. 13 (5): 305–14. PMID 12630679. 
  3. Tsimberidou AM, Alvarado Y, Giles FJ (August 2002). "Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies". Expert Rev Anticancer Ther 2 (4): 437–48. PMID 12647987. doi:10.1586/14737140.2.4.437. 
  4. Bernstein LR (1998). "Mechanisms of therapeutic activity for gallium" (PDF). Pharmacol. Rev. 50 (4): 665–682. PMID 9860806. 

Vidi još[uredi - уреди | uredi izvor]

Vanjske veze[uredi - уреди | uredi izvor]